MA
ADPT icon

Mutual Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

Mutual Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,040
Closed -$44.6K – 1088
2024
Q2 		$44.6K Buy
+10,040
New +$31.9K ﹤0.01% 1071

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AAP
Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Mutual Advisors's ADPT Position: Q3 2024 in Review

Mutual Advisors sold out of Adaptive Biotechnologies (ADPT) in Q3 2024, closing a stake of 10,040 shares — an estimated $44.6K sold.

Mutual Advisors first reported a position in ADPT in Q2 2024 and held it in 1 quarter. The position peaked at $44.6K in Q2 2024. 187 funds tracked by Wall St. Rank hold ADPT as of Q3 2024.

  • Mutual Advisors reported no remaining Adaptive Biotechnologies position as of Q3 2024 after selling out during the quarter.
  • Mutual Advisors sold 10,040 Adaptive Biotechnologies shares in Q3 2024, an estimated $44.6K.
  • Mutual Advisors first reported a position in Adaptive Biotechnologies in Q2 2024 and held it in 1 quarter.
  • Mutual Advisors's Adaptive Biotechnologies position peaked at $44.6K in Q2 2024.
  • 187 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2024.

Based on Mutual Advisors's 13F filing for Q3 2024, filed 25 Oct 2024.